EXEL•benzinga•
Exelixis Reports Final 5-Year Follow-Up Results From CheckMate -9ER Trial Evaluating CABOMETYX In Combination With Opdivo In Patients With Advanced Kidney Cancer At ASCO GU 2025; Shows Survival Benefit Compared With Sunitinib; Long-Term Efficacy Seen Acro
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 17, 2025 by benzinga